Search results (243)
« Back to PublicationsUnderstanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma.
Journal article
Fuentes-Lacouture M-C. et al, (2026), FEBS J
The challenge of defining and understanding monoclonal gammopathy of undetermined significance.
Journal article
Haslam A. et al, (2026), Br J Haematol
Early plasma proteomic alterations precede amyloidosis diagnosis, reflecting cardiac and immune dysregulation
Preprint
Hasheminasab SA. et al, (2026)
Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD dataset.
Journal article
Vijjhalwar R. et al, (2026), Osteoporos Int, 37, 727 - 736
High-throughput monoclonal gammopathy community monitoring programme.
Journal article
Agarwal G. et al, (2026), Br J Haematol
Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma.
Journal article
Foster KA. et al, (2026), Nat Commun
SECURE study: Incidentally detected MGUS patients have comparable depression and anxiety rates to UK general population.
Conference paper
Knight ES. et al, (2026), Br J Haematol, 208, 325 - 328
Biochemical bone biomarkers in plasma cell dyscrasias for the British Journal of Haematology
Journal article
Nador G. et al, (2026), British Journal of Haematology
High-risk smoldering myeloma - a case for early intervention?
Journal article
Krishnamoorthi A. et al, (2025), Curr Opin Oncol, 37, 650 - 657
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.
Journal article
Agarwal G. et al, (2025), Br J Haematol, 207, 2167 - 2172
Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study.
Journal article
Choi S. et al, (2025), Blood Cancer J, 15
Joint modeling of progression-free survival and patient-reported outcomes to evaluate the association between disease progression and symptoms among patients with relapsed/refractory multiple myeloma.
Journal article
Knop S. et al, (2025), J Patient Rep Outcomes, 9
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.
Journal article
Terpos E. et al, (2025), Am J Hematol, 100, 1839 - 1850
Belantamab Mafodotin Triggers Immune Invigoration in Multiple Myeloma Via Inflammatory and Immunogenic Cell Death
Preprint
Watson ECR. et al, (2025)
Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis.
Journal article
Fieggen J. et al, (2025), Blood Adv, 9, 3766 - 3770